BioPharmSignal logoBioPharmSignal

Biotech News

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Arvinas, Inc. (ARVN)Arvinas, Inc.Clinical readout

– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease – NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new

Related news

ARVNArvinas, Inc.2026-03-18 11:00 EST

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

ARVNArvinas, Inc.2026-02-24 12:00 EST

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

KYMRKymera2026-06-09 11:00 EST

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

ZNTLZentalis2026-05-21 21:39 EST

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

ENTAEnanta Pharmaceuticals2026-04-13 11:00 EST

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria

CCCCC4 Therapeutics2026-02-23 12:00 EST

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

FULCFulcrum Therapeutics2026-02-17 13:00 EST

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

NRIXNurix Therapeutics2026-08-04 11:00 EST

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

CCCCC4 Therapeutics2026-06-11 11:00 EST

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

View all latest news

Arvinas, Inc.

Arvinas is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ARVNArvinas, Inc.2026-06-04 12:00 EST

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

ARVNArvinas, Inc.2026-05-29 20:01 EST

Arvinas to Present at Jefferies Global Healthcare Conference

ARVNArvinas, Inc.2026-05-18 14:30 EST

Arvinas Employees Give Back During Company-wide Impact Day

ARVNArvinas, Inc.2026-05-12 11:05 EST

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

ARVNArvinas, Inc.2026-05-12 11:00 EST

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Stock data

Close
10.78 USD
Market cap
695.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States